葡萄糖类-1类似物:奇迹药物正在勃发展?
Binbin Gong1, Zhihong Yao1, Chenxu Zhou2
1College of Medicine, Jiaxing University, Jiaxing, 314001, China; College of Pharmacy, Zhejiang University of Technology, Hangzhou, 310000, China.
European journal of medicinal chemistry
|March 26, 2024
概括
类似葡萄糖-1 (GLP-1) 对于治疗2型糖尿病和肥胖至关重要. 新型单分子多激素激剂,如蒂尔泽帕提德,将GLP-1与其他激素结合起来,以克服现有疗法的局限性.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖的-1 (GLP-1) 对于葡萄糖平衡和食欲调节至关重要,在2型糖尿病 (T2DM) 和肥胖管理中发挥关键作用.
- 原生GLP-1的治疗效用受到其通过二乙酶-IV (DPP-IV) 和膜过的快速降解的限制,导致半衰期短.
研究的目的:
- 审查GLP-1的生理作用.
- 探索各种旨在延长GLP-1半衰期的结构修改.
- 讨论一种新兴的单分子多动因子药物类别,以提泽帕提德为例,用于T2DM和肥胖症治疗.
主要方法:
- 关于GLP-1生理学,结构修饰和新型治疗剂的文献综述.
- 对当前GLP-1受体激动剂及其局限性的分析.
- 检查单分子多激素剂的发展和潜力.
主要成果:
- 通过结构修改,GLP-1类似物已被开发出来,其半衰期延长.
- 目前的GLP-1受体激动剂显示出显著的疗效,但存在局限性.
- 单分子多激素剂代表了一个有前途的进步,将GLP-1与其他激素结合起来,以增强治疗效果.
结论:
- GLP-1类似物和单分子多激素剂为T2DM和肥胖症提供了显著的治疗潜力.
- 对基于GLP-1的疗法进行进一步的研究是有必要的.
- 蒂尔泽帕提德和类似的药物标志着代谢疾病治疗的新时代.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196


